You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.
Quest expects to deploy the pooled sample technique at its laboratories in Chantilly, Virginia and Marlborough, Massachusetts by the end of next week with additional laboratories to follow.
The assays are performed on nasal swab specimens self-collected by patients under the observation of a healthcare provider via telemedicine.
The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
Last month, Quest Diagnostics received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
MicroGen Dx's Texas-based lab is the only commercial laboratory in the US offering sputum testing for SARS-CoV-2.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.